U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 2C2H4NO2.Zn
Molecular Weight 213.526
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ZINC GLYCINATE

SMILES

[Zn++].NCC([O-])=O.NCC([O-])=O

InChI

InChIKey=UOXSXMSTSYWNMH-UHFFFAOYSA-L
InChI=1S/2C2H5NO2.Zn/c2*3-1-2(4)5;/h2*1,3H2,(H,4,5);/q;;+2/p-2

HIDE SMILES / InChI

Molecular Formula Zn
Molecular Weight 65.409
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C2H4NO2
Molecular Weight 74.0587
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Zinc monocarbonate (Zinc Carbonate) is an inorganic salt. In the United States, Zinc Carbonate may be used as an active ingredient in OTC drug products. When used as an active drug ingredient, the established name is Zinc Carbonate. Zinc monocarbonate is generally recognized as safe by FDA. It is used as skin protectant active ingredient. Zinc carbonate was found to retard the degradation of some poly(lactide-co-glycolide) (PLG) microspheres in vivo and in vitro. Adding Zinc Carbonate is essential during the preparation of PLGA microspheres. It can remarkably improve the stability of drugs in the acid microenvironment inside PLGA microspheres.

CNS Activity

Curator's Comment: Spatial memory deficits in a mouse model of late-onset Alzheimer's disease were caused by Zinc Carbonate supplementation. Long-term dietary administration of zinc ( Zinc Carbonate) can lead to impairments in cognitive function in rats. Microprobe synchrotron X-ray fluorescence (microSXRF) confirmed that brain zinc levels were increased by adding Zinc Carbonate to the drinking water.

Originator

Curator's Comment: Protherics that initially developed Voraxaze was acquired by BTG International in 2008. After the acquisition BTG International completed the development of Voraxaze and submitted the product for US approval.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Unknown

Approved Use

Unknown
Primary
CORTROPHIN-ZINC

Approved Use

Treatment of ulcerative colitis and other colonic disorders.

Launch Date

1955
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Secondary
VORAXAZE

Approved Use

Indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function. Limitation of use: VORAXAZE is not indicated for use in patients who exhibit the expected clearance of methotrexate (plasma methotrexate concentrations within 2 standard deviations of the mean methotrexate excretion curve specific for the dose of methotrexate administered) or those with normal or mildly impaired renal function because of the potential risk of subtherapeutic exposure to methotrexate.

Launch Date

2012
Primary
VUSION

Approved Use

INDICATIONS AND USAGE VUSION Ointment is indicated for the adjunctive treatment of diaper dermatitis only when complicated by documented candidiasis (microscopic evidence of pseudohyphae and/or budding yeast), in immunocompetent pediatric patients 4 weeks and older. A positive fungal culture for Candida albicans is not adequate evidence of candidal infection since colonization with C. albicans can result in a positive culture. The presence of candidal infection should be established by microscopic evaluation prior to initiating treatment. VUSION Ointment should be used as part of a treatment regimen that includes measures directed at the underlying diaper dermatitis, including gentle cleansing of the diaper area and frequent diaper changes.

Launch Date

2006
Primary
ZINC OXIDE

Approved Use

Unknown
Primary
ZINC SULFATE

Approved Use

Unknown

Launch Date

1987
Primary
ZINC SULFATE

Approved Use

Unknown

Launch Date

1987
Primary
ZINC SULFATE

Approved Use

Unknown

Launch Date

1987
PubMed

PubMed

TitleDatePubMed
In vitro activity of zinc salts against human rhinoviruses.
1987 Apr
Quadrupolar perturbed 14N NMR in the structurally commensurate and incommensurate phases of ammonium tetrachlorozincate.
1991 Apr 1
Topical zinc oxide treatment increases endogenous gene expression of insulin-like growth factor-1 in granulation tissue from porcine wounds.
1994 Dec
New applications for the zinc iodide-osmium tetroxide technique.
1994 Feb
Iron chelators as therapeutic agents against Pneumocystis carinii.
1994 May
Effects of trace metal compounds on HIV-1 reverse transcriptase: an in vitro study.
1999 May
Combined effects of argon laser irradiation and fluoride treatments in prevention of caries-like lesion formation in enamel: an in vitro study.
1999 Spring
Comparison of the levels of copper, zinc and iron in cervical mucus and in blood serum of women of childbearing age.
2004
Lysine beta311 of protein geranylgeranyltransferase type I partially replaces magnesium.
2004 Jul 16
Inhibition by copper(II) binding of hepatocyte growth factor (HGF) interaction with its receptor Met and blockade of HGF/Met function.
2004 Jul 30
Impact of the mother's zinc deficiency on the woman's and newborn's health status.
2005
Zinc in attention-deficit/hyperactivity disorder.
2005 Aug
Low dietary zinc decreases erythrocyte carbonic anhydrase activities and impairs cardiorespiratory function in men during exercise.
2005 May
Effects of zinc supplementation in patients with type 1 diabetes.
2005 Summer
Characterization and inhibition of SARS-coronavirus main protease.
2006
Zinc nutritional status of morbidly obese patients before and after Roux-en-Y gastric bypass: a preliminary report.
2006 Apr
Elevated cortical zinc in Alzheimer disease.
2006 Jul 11
Marginal zinc deficiency increased the susceptibility to acute lipopolysaccharide-induced liver injury in rats.
2006 May
Zinc homeostasis in aging: two elusive faces of the same "metal".
2006 Summer
Metal oxide nanoparticles induce unique inflammatory footprints in the lung: important implications for nanoparticle testing.
2010 Dec
Difficulty measuring methotrexate in a patient with high-dose methotrexate-induced nephrotoxicity.
2010 Dec
Oxidative stress, calcium homeostasis, and altered gene expression in human lung epithelial cells exposed to ZnO nanoparticles.
2010 Feb
Engineered nanomaterials cause cytotoxicity and activation on mouse antigen presenting cells.
2010 Jan 12
Phosphorylation of p65 is required for zinc oxide nanoparticle-induced interleukin 8 expression in human bronchial epithelial cells.
2010 Jul
ZnO nanoparticles induce apoptosis in human dermal fibroblasts via p53 and p38 pathways.
2011 Dec
Quantum dots trigger immunomodulation of the NFκB pathway in human skin cells.
2011 Jul
High-dose methotrexate-induced renal dysfunction: is glucarpidase necessary for rescue?
2011 Mar 1
Responses of human cells to ZnO nanoparticles: a gene transcription study.
2011 Nov
Zinc induces chemokine and inflammatory cytokine release from human promonocytes.
2011 Nov 30
Safety evaluation of sunscreen formulations containing titanium dioxide and zinc oxide nanoparticles in UVB sunburned skin: an in vitro and in vivo study.
2011 Sep
Zeta potential and solubility to toxic ions as mechanisms of lung inflammation caused by metal/metal oxide nanoparticles.
2012 Apr
Zinc oxide nanoparticles interfere with zinc ion homeostasis to cause cytotoxicity.
2012 Feb
Aerosolized ZnO nanoparticles induce toxicity in alveolar type II epithelial cells at the air-liquid interface.
2012 Feb
Glucarpidase for the treatment of life-threatening methotrexate overdose.
2012 Nov
Zinc oxide nanoparticles inhibit Ca2+-ATPase expression in human lens epithelial cells under UVB irradiation.
2013 Dec
Standard molar enthalpy of combustion and formation of quaternary ammonium tetrachlorozincate [n-CnH2n+1 N(CH3)3]2 ZnCl4.
2013 Dec
Sensitivity of human dental pulp cells to eighteen chemical agents used for endodontic treatments in dentistry.
2013 Jan
TiO2, CeO2 and ZnO nanoparticles and modulation of the degranulation process in human neutrophils.
2013 Jul 31
Inorganic salts in atmospheric particulate matter: Raman spectroscopy as an analytical tool.
2013 Nov
Cytotoxicity in the age of nano: the role of fourth period transition metal oxide nanoparticle physicochemical properties.
2013 Nov 25
Nanosized zinc oxide particles do not promote DHPN-induced lung carcinogenesis but cause reversible epithelial hyperplasia of terminal bronchioles.
2014 Jan
Additive effect of zinc oxide nanoparticles and isoorientin on apoptosis in human hepatoma cell line.
2014 Mar 3
Efficacy of glucarpidase (carboxypeptidase g2) in patients with acute kidney injury after high-dose methotrexate therapy.
2014 May
Glucarpidase for the management of elevated methotrexate levels in patients with impaired renal function.
2014 May 15
Practical considerations for the administration of glucarpidase in high-dose methotrexate (HDMTX) induced renal dysfunction.
2015 Sep
Comparable efficacy with varying dosages of glucarpidase in pediatric oncology patients.
2015 Sep
Spectroscopic probe to contribution of physicochemical transformations in the toxicity of aged ZnO NPs to Chlorella vulgaris: new insight into the variation of toxicity of ZnO NPs under aging process.
2016 Oct
Patents

Sample Use Guides

Rats: The dosage of zinc fluoride tetrahydrate (ZnF2 •4H2O) was adjusted to contain 2.1 mg (low-dose group, LG), 4.3 mg (mid-dose group, MG), and 5.4 mg fluoride per 200 g rat body weight (high-dose group, HG) corresponding to 5, 10, and 12.5 % of LD50 values for NaF.
Route of Administration: Oral
In Vitro Use Guide
Prepared ground human enamel specimens were immersed in zinc fluoride solutions containing 250 and 750 ppm F- at pH 6 and 4 for 4 min.
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:26:46 GMT 2023
Edited
by admin
on Fri Dec 15 16:26:46 GMT 2023
Record UNII
681VJX72FE
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ZINC GLYCINATE
INCI   WHO-DD  
INCI  
Official Name English
BIS(GLYCINATO-N,O)ZINC
Common Name English
Zinc glycinate [WHO-DD]
Common Name English
ZINC BIS(AMINOACETATE)
Systematic Name English
GLYCINE ZINC CHELATE
Common Name English
GLYCINE ZINC SALT
Common Name English
GLYCINE, ZINC SALT (2:1)
Common Name English
Zinc amino acid chelate [WHO-DD]
Common Name English
ZINC(II) GLYCINATE
Systematic Name English
Zinc bis glycinate chelate [WHO-DD]
Common Name English
ZINC CHELAZOME
Common Name English
(T-4)-BIS(GLYCINATO-N,O)ZINC
Common Name English
BIS(GLYCINATO)ZINC
Common Name English
ZINC GLYCINATE [INCI]
Common Name English
ZINC AMINO ACID CHELATE [VANDF]
Common Name English
ZINC BISGLYCINATE
Systematic Name English
Classification Tree Code System Code
DSLD 137 (Number of products:9660)
Created by admin on Fri Dec 15 16:26:46 GMT 2023 , Edited by admin on Fri Dec 15 16:26:46 GMT 2023
Code System Code Type Description
FDA UNII
681VJX72FE
Created by admin on Fri Dec 15 16:26:46 GMT 2023 , Edited by admin on Fri Dec 15 16:26:46 GMT 2023
PRIMARY
DRUG BANK
DB14493
Created by admin on Fri Dec 15 16:26:46 GMT 2023 , Edited by admin on Fri Dec 15 16:26:46 GMT 2023
PRIMARY
DAILYMED
681VJX72FE
Created by admin on Fri Dec 15 16:26:46 GMT 2023 , Edited by admin on Fri Dec 15 16:26:46 GMT 2023
PRIMARY
PUBCHEM
151910
Created by admin on Fri Dec 15 16:26:46 GMT 2023 , Edited by admin on Fri Dec 15 16:26:46 GMT 2023
PRIMARY
EPA CompTox
DTXSID60162193
Created by admin on Fri Dec 15 16:26:46 GMT 2023 , Edited by admin on Fri Dec 15 16:26:46 GMT 2023
PRIMARY
SMS_ID
300000011643
Created by admin on Fri Dec 15 16:26:46 GMT 2023 , Edited by admin on Fri Dec 15 16:26:46 GMT 2023
PRIMARY
RXCUI
806626
Created by admin on Fri Dec 15 16:26:46 GMT 2023 , Edited by admin on Fri Dec 15 16:26:46 GMT 2023
ALTERNATIVE
RXCUI
1306063
Created by admin on Fri Dec 15 16:26:46 GMT 2023 , Edited by admin on Fri Dec 15 16:26:46 GMT 2023
PRIMARY
ECHA (EC/EINECS)
238-173-1
Created by admin on Fri Dec 15 16:26:46 GMT 2023 , Edited by admin on Fri Dec 15 16:26:46 GMT 2023
PRIMARY
CAS
14281-83-5
Created by admin on Fri Dec 15 16:26:46 GMT 2023 , Edited by admin on Fri Dec 15 16:26:46 GMT 2023
PRIMARY
EVMPD
SUB22939
Created by admin on Fri Dec 15 16:26:46 GMT 2023 , Edited by admin on Fri Dec 15 16:26:46 GMT 2023
PRIMARY
MESH
C016838
Created by admin on Fri Dec 15 16:26:46 GMT 2023 , Edited by admin on Fri Dec 15 16:26:46 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY